Cargando…
Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing
Mixed dyslipidemia is a common lipid disorder characterized by the presence of an atherogenic lipoprotein phenotype due to abnormalities in various atherogenic and anti-atherogenic lipoproteins. Despite the link between the decrease of LDL-cholesterol by statin treatment and the prevention of cardio...
Autor principal: | Farnier, Michel |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605343/ https://www.ncbi.nlm.nih.gov/pubmed/19183747 |
Ejemplares similares
-
Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population
por: Patel, Piyush, et al.
Publicado: (2016) -
Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
por: Alagona, Peter
Publicado: (2010) -
Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy
por: Tarantino, Nicola, et al.
Publicado: (2017) -
Pleiotropic Action of Short-Term Metformin and Fenofibrate Treatment, Combined With Lifestyle Intervention, in Type 2 Diabetic Patients With Mixed Dyslipidemia
por: Pruski, Maciej, et al.
Publicado: (2009) -
Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism
por: Liu, Huixing, et al.
Publicado: (2022)